John Reed, Sanofi R&D chief (Jeff Rumans)
Sanofi flashes more PhIII data on new multiple myeloma drug, setting up battle with Darzalex
Two months after nabbing their first approved cancer drug in a decade, Sanofi announced new late-stage data burnishing the drug’s efficacy in another combination …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
